Latest Viral load Stories

Study among people with HIV People with HIV are more likely to keep their scheduled medical appointments — and their disease under control — if they feel their physician listens, explains things clearly and knows them as a person, not just a "case," new Johns Hopkins research suggests. "If people feel their doctor really knows them and listens to them, they feel that doctor has their best interests at heart and may be more likely to follow medical advice," says study leader Tabor E....

Avail is conducting a 12-week, Phase 2, Randomized Study to Evaluate the Safety and Efficacy of a new drug in Subjects with Chronic Hepatitis C Infection. DeLand, Florida (PRWEB) June 03, 2013 *To see if you qualify for this Hepatitis C Clinical Trial, visit Avail Clinical Research on the web or contact us directly at (386) 785-2404. BACKGROUND The Hepatitis C virus (HCV) infection is a global public health problem. The global prevalence of hepatitis C infection is estimated to average 3%...

The Optical Society To test the severity of a viral infection, clinicians try to gauge how many viruses are packed into a certain volume of blood or other bodily fluid. This measurement, called viral load, helps doctors diagnose or monitor chronic viral diseases such as HIV/AIDS and hepatitis. However, the standard methods used for these tests are only able to estimate the number of viruses in a given volume of fluid. Now two independent teams have developed new optics-based methods for...

Unprecedented Immune Reconstitution Drives HIV Viral Reservoir Depletion RICHMOND, Calif., May 15, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new clinical data from its program to develop a ZFP Therapeutic(®) for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, are being presented at the 16(th) Annual Meeting of the American Society of Gene and...

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Through the publication of CEO notes, I seek to provide shareholders and other interested parties with a level of corporate transparency often absent in the microcap marketplace. In recent notes, I reviewed various topics, including emerging opportunities in cancer and the expansion of our government contract program to create a...

- Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). The designation is based, in part, on...

SAN DIEGO, April 18, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that a poster presentation entitled: "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens," is being presented today at the International Society of Extracellular Vesicles (ISEV) 2013 conference being held in Boston, MA. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give...

SAN DIEGO, April 16, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. As disclosed in yesterday's SEC form 8-K submission, we entered into a subcontract agreement with Battelle Memorial Institute (Battelle) to provide services underlying a $22.8 million prime contract that was recently awarded to Battelle by the Defense Advanced Research Projects Agency (DARPA). The objective of this contract...

U.S. Department of Health and Human Services issues medical guidelines recommending genotypic testing to aid HIV therapy selection MADISON, N.J., March 27, 2013 /PRNewswire/ -- A new test based on gene sequencing may be used to assess a patient's suitability for treatment with CCR5 antagonists, a class of HIV antiretroviral therapies, under new medical guidelines issued by the U.S. Department of Health and Human Services (DHHS). The new genotypic test performs comparably to the...

Models could improve the treatment of HIV patients in countries with limited resources Results of a study published online in the Journal of Antimicrobial Chemotherapy today (Thursday), demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models...